RECOVERY & TISSUE REPAIR RESEARCH / COLOPHON
Contact the Editorial Desk
Correspondence on citations, corrections, and research-related inquiries — the things a reference desk is most useful to hear about.
Editorial correspondence
The correspondence worth most here is about the record itself: a citation we quoted wrong, a newly published study on GLOW's constituents, KPV, or TB-500, or a regulatory or WADA-status change that reframes a finding. Every such note is checked before anything on the site changes.
The most actionable messages specify the page, the exact passage in question, and a supporting reference — a DOI or PubMed identifier where possible — so the proposed correction can be verified against its source.
Editorial mailbox: editors@carolinapeptide.com
What this desk cannot do
This is a comparative reading of a literature, not a clinical service. It will not counsel or endorse human use of GLOW, KPV, or TB-500; will not name a dose or schedule for anyone; will not judge whether an animal or preclinical result carries over to a particular person; and will not help buy, sell, or track down any compound from any supplier. Since TB-500 — and through it GLOW — sits on WADA's Prohibited List, questions of athletic eligibility get only the bare fact of that prohibited status and nothing more. None of the three is FDA-approved. For medical guidance, see a licensed clinician where you live. Replies to correspondence are not promised, and this mailbox is checked only now and then.